Amgen says drug combo cuts risk of death by 58% in patients with aggressive lung cancer

CNBC
Amgen says drug combo cuts risk of death by 58% in patients with aggressive lung cancer
A drug from Amgen could give patients with an aggressive form of lung cancer significantly more time to live when added to an immunotherapy from AstraZeneca.
Read the full story
This is a short summary. The complete article is published by CNBC.
Continue at CNBC

Headline and summary aggregated from public news feeds. For information only — not financial advice.

More in Markets

CNBC • 1h ago
AI build-out hits snag as Google and Microsoft put off raising capex forecasts
BusinessWire • 1h ago
Third Space Partners Acquires Quest Events, National Leader in Live Event Drape and Modular Scenic Solutions
CNBC • 2h ago
Warren urges DOJ criminal probe of Bank of America over anti-money-laundering violations
All Markets news